Eric Devroe - 01 Mar 2024 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRV	Stock Option (Right to Buy)	Award	$0	+90,090		$0.000000	90,090	01 Mar 2024	Common Stock	90,090	$5.70	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2025, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.